Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zytiga | Abiraterone | Withdrawn | ||||
| Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
| Verzenio | Abemaciclib | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Active | |||
| Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Orencia | Abatacept | Arthritis, rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Orencia | Abatacept | Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Orencia | Abatacept | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn |
Last Updated : April 28, 2024